At the 67th annual meeting of the American Society of Hematology, Galapagos NV presented new Phase 2 data from the ATALANTA-1 study. This study assesses the CAR T cell therapy, GLPG5101, in patients with relapsed or refractory mantle cell lymphoma (MCL). The results indicate high rates of complete responses and minimal residual disease negativity, with durable responses. As of September 2, 2025, 26 patients had undergone leukapheresis, and 25 had received an infusion of GLPG5101, with a dropout rate of 4%.
Intention to Discontinue Cell Therapy Operations
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Galapagos reiterated its intention to discontinue its cell therapy operations, as announced on October 21, 2025. The company continues to conduct its ongoing clinical studies and may consider any viable proposals for the acquisition of all or part of its cell therapy business during this cessation process.
About GLPG5101
GLPG5101 is a second-generation anti-CD19/4-1BB CAR-T candidate product, evaluated for its safety, efficacy, and the feasibility of its decentralized manufacturing in the ATALANTA-1 study. The primary objective of Phase 2 is to assess the objective response rate, while secondary objectives include the complete response rate, duration of response, and overall survival. The study is currently recruiting patients in the United States and Europe.
SectorSanté · Biotechnologies · Vaccins et laboratoires de recherche›Biotechnologie
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: 1T2026
Key reported figures
Revenue: 6.5M€
Net income: 14.5M€
Guidance from the release
Je suis particulièrement enthousiasmé par les progrès que nous réalisons.
Risks mentioned
Risque que la transaction avec Gilead ne soit pas finalisée dans les délais prévus.
Risques liés à la disponibilité des ressources financières pour des transactions stratégiques.
Incertitude liée aux coûts de restructuration d'environ 125 millions d'euros à 175 millions d'euros.
Opportunities identified
Opportunité de finaliser la collaboration avec Gilead au deuxième trimestre 2026.
Possibilité de dépenses jusqu'à 500 millions USD pour le développement commercial.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
